This presentation includes forward-looking statements about, among other topics, Pfizer's mRNA strategy and pipeline portfolio; Pfizer’s collaboration agreement with
BioNTech to co-develop a shingles mRNA vaccine; Pfizer’s collaboration with Beam Therapeutics for base editing for certain rare diseases; Pfizer’s option agreement with
Acuitas to non-exclusively license LNP technology; Pfizer’s research collaboration with Codex DNA for its synthetic DNA technology; our efforts to respond to COVID19, including Comirnaty; our anticipated future operating and financial performance, business plans and prospects; our ability to successfully capitalize on growth
opportunities and prospects; and other statements about our business, operations and financial results that are each subject to substantial risks and uncertainties
that could cause actual results to differ materially from those expressed or implied by such statements.
相关推荐
热门下载
推荐
快速链接
热门标签
关注我们
扫码关注我们
了解更多相关信息